 TEL AVIV, Israel, Oct. 31, 2019 PRNewswire -- Galmed Pharmaceuticals Ltd. GLMD Galmed or the Company, a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 34 clinical trial for the treatment of nonalcoholic steatohepatitis NASH and fibrosis announced today that it will present new data at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases AASLD in Boston, November 8-12, 2019. This new pre-clinical data elucidates the mechanism by which Aramchol affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the Companys Phase IIb trial. The data suggests that Aramchol improves liver glucose homeostasis in patients and murine models. 